Why the study?
Heart failure with preserved ejection fraction has become the predominant HF syndrome and new therapies and diagnostic biomarkers have emerged recently.
Answers are grounded in this paper and cite their sources.
This review outlines the changing paradigms in heart failure management in 2013, highlighting the emergence of HFpEF, biomarker-guided therapy, and new pharmacological and device interventions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Akshyaya Pradhan (2013) conducted a review in Heart failure. Heart failure management strategies was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: